MedCity News September 30, 2024
Bristol Myers Squibb is turning to the prime-editing technology of Prime Medicines for the R&D of new cell therapies for cancer and immunology. The pharma giant is paying $110 million up front to begin the collaboration.
Prime Medicine, a biotech company that set out to use its more precise approach to gene editing to develop new one-time treatments for rare diseases, is expanding its scope to more prevalent therapeutic areas under a new partnership with Bristol Myers Squibb.
The pharmaceutical giant struck a deal for an exclusive global license to Prime Medicine’s technology, which will be used to develop next-generation ex vivo T cell therapies for oncology and immunology. The deal terms announced Monday call for BMS to pay $110...
Today's Sponsors
Today's Sponsor